Cargando…
The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis
Immunotherapy is the main standard treatment for non-small cell lung cancer (NSCLC) patients. Immune suppressive cells in tumor microenvironment can counteract its efficacy. Myeloid-derived suppressor cells (MDSCs) include two major subsets: polymorphonuclear (PMN-MDSCs) and monocytic (M-MDSCs). Man...
Autores principales: | Bronte, Giuseppe, Calabrò, Luana, Olivieri, Fabiola, Procopio, Antonio Domenico, Crinò, Lucio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460713/ https://www.ncbi.nlm.nih.gov/pubmed/36401744 http://dx.doi.org/10.1007/s10238-022-00946-6 |
Ejemplares similares
-
Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors
por: Bronte, Giuseppe, et al.
Publicado: (2021) -
High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis
por: Bronte, Giuseppe, et al.
Publicado: (2022) -
Complexity and Challenges in Defining Myeloid-Derived Suppressor Cells
por: Damuzzo, Vera, et al.
Publicado: (2015) -
Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach?
por: Bronte, Giuseppe, et al.
Publicado: (2023) -
Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression
por: Pinton, Laura, et al.
Publicado: (2015)